Skip to content

Guardant Health Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 5, 2026 results vs estimates

Guardant Health Inc · E.GH.NASDAQ · United States
Use symbol E.GH.NASDAQ in our API & Excel add-in to retrieve this data ↓
185.31
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 51.55%

Guardant Health Inc Forecast

Guardant Health Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 51.6% a year, a typical one-standard-deviation range is 171.85–198.77 over a week, 157.73–212.89 over a month and 89.78–280.84 over a year. (Signals as of 1 Nov 2026.)

Guardant Health Inc Price Chart

MacroFinance.ai

Guardant Health Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Guardant Health Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Guardant Health Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Guardant Health Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Guardant Health Inc
P/S
19.48x
Stretched vs own history
QoQ +2.2%
YoY +33.1%
now 19.477710.3 low20.41 high
ⓘP/S As of 22 Nov 2026.See Guardant Health Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Guardant Health Inc
EV/Sales
20.00x
Stretched vs own history
QoQ +2.0%
YoY +29.3%
now 19.997410.82 low20.97 high
ⓘEV/Sales As of 22 Nov 2026.See Guardant Health Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Guardant Health Inc
FCF Yield
-0.9%
Strong vs own history
QoQ −12.7%
YoY −53.1%
now -0.932-2.3 low-0.93 high
ⓘFCF Yield As of 22 Nov 2026.See Guardant Health Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Guardant Health Inc
Earnings Yield
-1.9%
Strong vs own history
QoQ −3.2%
YoY −35.5%
now -1.9473-4.12 low-1.91 high
ⓘEarnings Yield As of 22 Nov 2026.See Guardant Health Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Guardant Health Inc
Market Cap
$24.9B
Highest in 5 years
QoQ +10.5%
YoY +88.6%
now 24909.740810,112 low24,910 high
ⓘMarket Cap As of 22 Nov 2026.See Guardant Health Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Guardant Health Inc
Net Debt
$665M
High vs own history
QoQ +3.3%
YoY −11.0%
now 664.586508.54 low746.36 high
ⓘNet Debt As of 22 Nov 2026.See Guardant Health Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Guardant Health Inc
Current Ratio
3.60x
Weak vs own history
QoQ −10.6%
YoY +2.9%
now 3.63.5 low4.84 high
ⓘCurrent Ratio As of 22 Nov 2026.See Guardant Health Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Guardant Health Inc
Quick Ratio
3.35x
Weak vs own history
QoQ −9.8%
YoY +7.5%
now 3.34953.12 low4.56 high
ⓘQuick Ratio As of 22 Nov 2026.See Guardant Health Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Guardant Health Inc
Interest Coverage
-92.12x
Strong vs own history
QoQ −1.3%
YoY −21.4%
now -92.12-117.27 low-92.12 high
ⓘInterest Coverage As of 22 Nov 2026.See Guardant Health Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Guardant Health Inc
Piotroski F-Score
5
Mid-range vs own history
QoQ −16.7%
YoY +25.0%
now 54 low6 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Guardant Health Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Guardant Health Inc
Altman Z-Score
4.88
Strong vs own history
QoQ +9.5%
YoY +149.0%
now 4.88081.29 low4.88 high
ⓘAltman Z-Score As of 22 Nov 2026.See Guardant Health Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  17 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Guardant Health Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Guardant Health Inc fundamentals: income statement, balance sheet & cash flow

Guardant Health Inc reported revenue of $982.0m and net income of -$416.3m in FY2025, the year ended 31 December 2025 — revenue up 32.9% and net income up 4.6% on the prior year. Free cash flow was -$233.1m. These figures are as reported in the filings, not restated: 10 fiscal years and 40 quarters of history, back to December 2016. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$982.0m
+32.9%
Net income
-$416.3m
+4.6%
Gross margin
64.46%
Free cash flow
-$233.1m
+15.2%
Net debt
$1.33bn
Shares short (30 Oct 2026)
9.43m
5.38 days to cover
Guardant Health Inc income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue982.0739.0563.9449.5373.7
Cost of revenue349.0289.8227.1156.3122.9
Gross profit633.0449.2336.9293.2250.7
Research & development364.2347.8367.2373.8263.2
Selling, general & admin.706.1545.1534.4463.8—
Operating income-437.2-443.6-564.7-544.4-411.0
EBITDA-373.9-390.1-433.3-614.9-359.6
Interest expense3.92.62.62.62.6
Pre-tax income-417.5-435.1-478.8-653.4-384.5
Income tax-1.31.30.71.10.3
Net income-416.3-436.4-479.4-654.6-405.7

Download Guardant Health Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.GH.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks the full history, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Guardant Health Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Guardant Health Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Guardant Health Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Guardant Health Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Guardant Health Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Guardant Health Inc (United States)

Guardant Health Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Gamehost Inc.

Frequently asked questions

What is Guardant Health Inc?
Guardant Health Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Guardant Health Inc price?
The latest close is 185.31 (1 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Guardant Health Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Guardant Health Inc?
20-day realised volatility is 51.6% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 14.9% over a month and 7.3% over a week.
What factors affect Guardant Health Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Guardant Health Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Guardant Health Inc?
58 backtested tactical asset allocation strategies trade Guardant Health Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Guardant Health Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Guardant Health Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Guardant Health Inc historical data?
In the Free historical data section of this page: the last 10 years of Guardant Health Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Guardant Health Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Guardant Health Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.GH.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20145.83
2026-11-19145.59
2026-11-18145.14
2026-11-17143.28
2026-11-16144.03
2026-11-13151.7
2026-11-12154.86
2026-11-11154.78
2026-11-10155.35
2026-11-09158.79
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.